Bailard, Inc. Fulcrum Therapeutics, Inc. Transaction History
Bailard, Inc.
- $3.84 Billion
- Q4 2024
A detailed history of Bailard, Inc. transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Bailard, Inc. holds 35,900 shares of FULC stock, worth $131,753. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,900Holding current value
$131,753% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding FULC
# of Institutions
148Shares Held
51.8MCall Options Held
6.91MPut Options Held
1.89M-
Ra Capital Management, L.P. Boston, MA10.2MShares$37.5 Million0.51% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.25MShares$19.3 Million2.43% of portfolio
-
Black Rock Inc. New York, NY4.8MShares$17.6 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT4.78MShares$17.5 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$12 Million0.0% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $191M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...